Gilead Sciences (GILD) is back on investors’ radar after its new collaboration with Nucleai, which applies AI powered tissue analytics to antibody drug conjugate programs, alongside recently reported second quarter results and updated guidance.

Recent price action suggests investors are warming to Gilead Sciences again, with a 7 day share price return of 5.56% and a year to date share price return of 13.6% alongside the Nucleai collaboration, Q2 earnings update, slightly revised guidance and the latest dividend declaration. Over the longer term, the total shareholder return of 19.09% over 1 year and very strong gains over 3 and 5 years point to momentum that has built rather than faded.

If you are interested in how AI is changing healthcare more broadly, this could be a good moment to broaden your watchlist with 44 healthcare AI stocks

Gilead Sciences now trades at about US$138, sitting between a cluster of analyst targets near US$157 and one published fair value estimate close to US$128, while a separate DCF points far higher. Where does fair value really sit after this latest move?

Most Popular Narrative: 7.6% Overvalued

The most followed narrative on Gilead Sciences currently puts fair value at about $128 per share, below the last close of $138.14. That gap sits alongside a long list of pipeline and M&A assumptions that matter more than any single quarter.

Gilead is transitioning from a “single-franchise HIV company” into a multi-platform biopharma with high-probability growth drivers (lenacapavir, Trodelvy) and high-upside optionality (cell therapy, immunology). Temporary earnings headwinds are masking long-term value creation.

Want to see how that multi-platform story translates into the $128 fair value number? The narrative leans heavily on faster earnings growth, richer future margins and a premium profit multiple that is usually reserved for faster growing sectors. The exact mix of HIV cash flows, oncology ramp and cell therapy optionality is laid out in detail but the weighting across these drivers is not obvious at first glance. The full memo shows which piece carries the heaviest load in the valuation math.

Result: Fair Value of $128.38 (OVERVALUED)

However, this Gilead Sciences narrative could shift quickly if key trials disappoint or if the integration of recent acquisitions affects margins for longer than expected.

Another View: Market Ratios Point To Gilead Sciences As Cheap

That $128 fair value from the narrative sits awkwardly against how Gilead Sciences is actually priced on sales. The stock trades on a P/S of 5.6x, compared with 7.1x for peers and 11.4x for the wider US Biotechs industry, while the fair ratio suggests 9.8x. If the market edges closer to that fair ratio, current pricing may be leaving more room on the table than the narrative implies.

Next Steps

Sentiment around Gilead Sciences is clearly split, with both concerns and optimism in play. Take a moment to weigh the evidence yourself, then check the full picture across 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Gilead Sciences?

If you like the risk reward trade off in Gilead Sciences, do not stop there. Let the Simply Wall Street Screener surface more targeted opportunities for you.

• Target dependable income by scanning companies that qualify as 11 dividend fortresses and see which ones could strengthen the yield side of your portfolio.
• Hunt for quality at a potential discount with the 51 high quality undervalued stocks and quickly spot stocks where fundamentals and pricing look out of sync.
• Prioritise resilience by focusing on the 88 resilient stocks with low risk scores so you do not miss companies with steadier profiles when markets turn choppy.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.